July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.
Detection of oral human papillomavirus (HPV) rose during the first 12 to 24 weeks of antiretroviral therapy in a prospective observational study of 388 people starting their first regimen.
STD screening not only identifies curable infections but STDs are also biologic markers of risk particularly for HIV transmission among some men who have sex with men (MSM).
From 2000 through mid-2010, 15% of New York City men already diagnosed with syphilis were infected with HIV, according to results of a population-level analysis.
Would you trust a computer to mix your cocktail? When it comes to your HIV medications, specially designed software programs may be doing just that in the future.